(Q36890181)

16 August 2017

1 reference

title

Valproic acid for the treatment of myeloid malignancies (English)

1 reference

16 August 2017

Norbert Gattermann

1 reference

16 August 2017

Andrea Kuendgen

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

110

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

943-954

1 reference

Valproate and valproate-analogues: potent tools to fight against cancer.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Antiepileptic teratogen valproic acid (VPA) modulates organisation and dynamics of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproic acid inhibits angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Hematologic toxicity of sodium valproate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Differential effects of histone deacetylase inhibitors on interleukin-18 gene expression in myeloid cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Modulation of angiogenesis-related protein synthesis by valproic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Treatment with valproic acid for myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22891

7 January 2021

Identifiers

DOI

10.1002/CNCR.22891

1 reference

16 August 2017

1 reference